REBYOTA™ Prospective Registry (ROAR)

REBYOTA™ for the Prevention of Recurrence of Clostridioides Difficile Infection (CDI) in Adult Patients: An Observational Study

  • Clinical Trial Information

    Trial Contact: Shepherd, Adriane R; Garcia de Djuro, Ginette

    Trial Phone: 321 841-2285 ; 321.841.6649

  • IRB No: W23.095.05

    Protocol Abbrev: ROAR-000422

    Principal Investigator: Udayakumar Navaneethan, MD

    Age Group: Adult

    Secondary Protocol No: 000422

    Treatment: Drug: REBYOTA™ ID: NCT05835219

  • Objective

    To describe the clinical effectiveness through 8 weeks after treatment with REBYOTA in real-world medical practice

  • Key Eligibility

    Inclusion Criteria:
    •  Signed and dated ICF
    •  Age ≥ 18 years
    •  Diagnosis of rCDI as determined by the treating physician.
    •  Completed antibiotic treatment for the presenting rCDI episode.
    •  Prescription for REBYOTA to prevent rCDI according to the approved indication.